Multiplexed analysis to detect gene fusions, 5/17

May 2017—Agena Bioscience announced a comparative study published in *Scientific Reports* (published online Feb. 9, 2017. doi:10.1038/srep42259) highlighting the use of its mass-spec-based platform for transcriptome analysis of *ALK, ROS1,* and *RET* gene fusions in lung cancer.

In this proof-of-principle study conducted at the Peter MacCullum Cancer Centre in Melbourne, Australia, Pfizer Oncology Research in San Diego, and Agena Bioscience, 51 clinical specimens were tested using three different transcriptome analysis platforms. The study included the Agena Bioscience LungFusion Panel, Nanostring Elements, and a Thermo Fisher Scientific NGS fusion panel. Results were measured against historical FISH and immunohistochemistry data with concordance ranging from 86 percent to 96 percent, depending on the platform used.

The LungFusion Panel demonstrated a 95 percent positive percent agreement and a 93 percent negative percent agreement with FISH. It was the only platform to detect a FISH positive RET fusion in the most degraded sample.

***Agena Bioscience**, 858-882-2800*